Effects of Cardiac Glycosides on RNA Expression in Prostate Cancer LNCaP-abl Cells

Prostate cancer is the most common cancer in men and cardiac glycosides inhibit prostate cancer cell proliferation. In order to investigate the mechanism by which cardiac glycosides inhibit prostate cancer cells, we observed genome-wide RNA expression in prostate cancer LNCaP-abl cells, hormone resistant cells, after the cardiac glycoside treatment using RNA-Seq. In addition, we profiled LNCaP-abl cells after androgen receptor (AR) knockdown to observe whether cardiac glycoside effect on RNA expression is similar to that of AR knockdown. Observation of three cardioglycosides, Digoxin, Peruvoside and Strophanthidin, and AR knockdown regulated RNA expression in LNCaP-abl with RNA-Seq (each triplicates)

前列腺癌是男性最常见的恶性肿瘤，强心苷类化合物可抑制前列腺癌细胞增殖。为探究强心苷抑制前列腺癌细胞的分子机制，本研究采用RNA测序（RNA-Seq）技术，检测了经强心苷处理的激素抵抗型前列腺癌细胞LNCaP-abl的全基因组RNA表达水平。此外，为观察强心苷对RNA表达的调控效应是否与雄激素受体（androgen receptor, AR）敲降相似，本研究还对雄激素受体敲降后的LNCaP-abl细胞进行了表达谱分析。本研究通过RNA测序对三种强心苷——地高辛（Digoxin）、杠柳苷元（Peruvoside）、毒毛旋花子苷元（Strophanthidin）——以及AR敲降处理的LNCaP-abl细胞的RNA表达进行了检测，每组均设置三次生物学重复。